Dr Javier Cortes speaks to ecancer about new data from the KEYNOTE-756 phase 3 clinical trial showing that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes.

He goes on to discuss the results presented at EBCC 2024, detailing how adding pembrolizumab to chemotherapy does not delay the time to surgery, and after surgery does not delay the start of adjuvant therapy.

Dr Cortes continues to discuss the consequences of these findings and how immunotherapy might also improve outcomes for this patient population.

He concludes by discussing what is next for this study highlighting areas where further research is still required.